Should I buy or sell Rhythm Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks .

What is Rhythm Pharmaceuticals' stock price target for 2024?

5 equities research analysts have issued twelve-month target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $55.00. On average, they anticipate the company's share price to reach $47.20 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts .

How have RYTM shares performed in 2024?

Rhythm Pharmaceuticals' stock was trading at $45.97 at the start of the year. Since then, RYTM shares have decreased by 17.1% and is now trading at $38.11. View the best growth stocks for 2024 here .

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RYTM earnings forecast .

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.70) EPS for the quarter, meeting analysts' consensus estimates of ($0.70). The firm earned $24.23 million during the quarter, compared to analyst estimates of $25.38 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative trailing twelve-month return on equity of 96.02%. The company's revenue for the quarter was up 175.7% on a year-over-year basis. During the same period last year, the business posted ($0.75) EPS.

What ETFs hold Rhythm Pharmaceuticals' stock?

ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) , ALPS Medical Breakthroughs ETF (SBIO) , BlackRock Future Health ETF (BMED) , SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU) . iShares Micro-Cap ETF (IWC) .

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV) , Gilead Sciences (GILD) , Sorrento Therapeutics (SRNE) , Exelixis (EXEL) , Viking Therapeutics (VKTX) , Amarin (AMRN) , Kadmon (KDMN) , Pfizer (PFE) , Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT) .

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.14%). Insiders that own company stock include Christopher Paul German, David P Meeker, Hunter C Smith , Jennifer Chien, Jennifer Kayden Lee , Joseph Shulman , Pamela J Cramer , William T Roberts and Yann Mazabraud . View institutional ownership trends .

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RYTM

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free RYTM Stock Alerts

$38.11

-0.34 (-0.88%)

(As of 04/18/2024 ET)

Compare

Today's Range: $37.62
▼
$38.90
50-Day Range: $38.11
▼
$52.44
52-Week Range: $15.50
▼
$52.57

Volume: 439,034 shs
Average Volume: 512,807 shs
Market Capitalization: $2.29 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $47.20

Get Rhythm Pharmaceuticals alerts:

Rhythm Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 23.9% Upside
$47.20 Price Target
Short Interest: Bearish
16.20% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.80
Upright™ Environmental Score
News Sentiment: 0.05
Based on 4 Articles This Week
Insider Trading: Selling Shares
$7.63 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.05) to ($1.97) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

450th out of 918 stocks

Pharmaceutical Preparations Industry

195th out of 402 stocks

2.5

Analyst's Opinion

Consensus Rating
Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Rhythm Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.20% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Rhythm Pharmaceuticals has recently increased by 5.87%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Rhythm Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rhythm Pharmaceuticals does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Rhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Rhythm Pharmaceuticals is -1.80.

2.2

News and Social Media Coverage

News Sentiment
Rhythm Pharmaceuticals has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Rhythm Pharmaceuticals this week, compared to 5 articles on an average week.
Search Interest
5 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
6 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,626,355.00 in company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.05) to ($1.97) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rhythm Pharmaceuticals is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rhythm Pharmaceuticals is -11.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rhythm Pharmaceuticals has a P/B Ratio of 13.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

RYTM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RYTM Stock News Headlines

April 4, 2024 | insidertrades.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 368 Shares

March 28, 2024 | marketbeat.com

7 Stocks That Will Drive the Weight Loss Drugs Market (RYTM)

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 23, 2024 | insidertrades.com

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 18,235 Shares of Stock

March 20, 2024 | insidertrades.com

Hunter C. Smith Sells 15,515 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

March 20, 2024 | insidertrades.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CEO Sells $1,784,274.68 in Stock

April 16, 2024 | globenewswire.com

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

April 14, 2024 | finance.yahoo.com

Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | americanbankingnews.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Rating Reiterated by Needham & Company LLC

April 11, 2024 | yahoo.com

Rhythm and Autism comes to Fertile Ground Festival

April 10, 2024 | markets.businessinsider.com

5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

April 10, 2024 | msn.com

Lee Brice coming to Rhythm City Casino

April 9, 2024 | msn.com

Hendersonville's 2024 Rhythm and Brews lineup announced

April 8, 2024 | msn.com

Rising Chorus: Rachana Shah and Rhythm Wagholikar’s Anthem for Prime Minister Modi

April 4, 2024 | msn.com

Headbangers: Rhythm Royale - Official Battle of the Dancers & Season 3 Launch Trailer

April 2, 2024 | msn.com

Rick Springfield to play Rhythm City in July

April 1, 2024 | globenewswire.com

Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing

March 25, 2024 | globenewswire.com

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

March 23, 2024 | msn.com

Watch: Singing dog Nova with "voice of an angel" performs Rhythm of the Night at RSPCA Sheffield shelter

March 22, 2024 | yahoo.com

Bongee Bear and the Kingdom of Rhythm Streaming: Watch & Stream Online via Amazon Prime Video

March 22, 2024 | finance.yahoo.com

Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM)

March 22, 2024 | msn.com

Rhythm City welcomes Banda Maguey

March 20, 2024 | finance.yahoo.com

Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM)

March 20, 2024 | finance.yahoo.com

Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ...

March 20, 2024 | finance.yahoo.com

Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares

March 19, 2024 | msn.com

Rhythm City, Davenport, will bloom with Gin Blossoms alt rock

See More Headlines

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RYTM
CUSIP: N/A
CIK: 1649904
Web: www.rhythmtx.com
Phone: (857) 264-4280
Fax: 857-264-4299
Employees: 226
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $47.20
High Stock Price Target: $55.00
Low Stock Price Target: $27.00
Potential Upside/Downside: +23.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-184,680,000.00
Net Margins: -238.50%
Pretax Margin: -237.79%
Return on Equity: -96.02%
Return on Assets: -55.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.58
Quick Ratio: 5.43

Sales & Book Value

Annual Sales: $77.43 million
Price / Sales: 29.60
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.87 per share
Price / Book: 13.28

Miscellaneous

Outstanding Shares: 60,140,000
Free Float: 57,313,000
Market Cap: $2.29 billion
Optionable: Optionable
Beta: 1.90

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. David P. Meeker M.D. (Age 70)
Chairman, President & CEO
Comp: $1.17M
Mr. Hunter C. Smith M.B.A. (Age 55)
CFO & Treasurer
Comp: $692.2k
Mr. Joseph Shulman (Age 49)
Chief Technical Officer
Comp: $608.2k
Mr. Yann Mazabraud (Age 51)
Executive VP & Head of International
Comp: $747.43k
Ms. Jennifer Lee (Age 48)
Executive VP & Head of North America
Comp: $644.2k
Mr. Christopher German (Age 53)
Corporate Controller, Principal Accounting Officer & Executive Director
Mr. David Connolly
Head of Investor Relations & Corporate Communications
Mr. Jim Flaherty
Senior VP & General Counsel
Ms. Sarah Ryan
Vice President of Sales & Marketing
Ms. Pamela J. Cramer (Age 50)
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RYTM Stock Analysis - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.
What is Rhythm Pharmaceuticals' stock price target for 2024?: 5 equities research analysts have issued twelve-month target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $55.00. On average, they anticipate the company's share price to reach $47.20 in the next year. This suggests a possible upside of 23.9% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.
How have RYTM shares performed in 2024?: Rhythm Pharmaceuticals' stock was trading at $45.97 at the start of the year. Since then, RYTM shares have decreased by 17.1% and is now trading at $38.11.
View the best growth stocks for 2024 here.
When is Rhythm Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our RYTM earnings forecast.
How were Rhythm Pharmaceuticals' earnings last quarter?: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.70) EPS for the quarter, meeting analysts' consensus estimates of ($0.70). The firm earned $24.23 million during the quarter, compared to analyst estimates of $25.38 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative trailing twelve-month return on equity of 96.02%. The company's revenue for the quarter was up 175.7% on a year-over-year basis. During the same period last year, the business posted ($0.75) EPS.
What ETFs hold Rhythm Pharmaceuticals' stock?: ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), BlackRock Future Health ETF (BMED), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of Rhythm Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).
When did Rhythm Pharmaceuticals IPO?: Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
Who are Rhythm Pharmaceuticals' major shareholders?: Rhythm Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.14%). Insiders that own company stock include Christopher Paul German, David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud.
View institutional ownership trends.
How do I buy shares of Rhythm Pharmaceuticals?: Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RYTM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Rhythm Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

RYTM Stock Price History

RYTM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RYTM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™